对《玻璃体腔药物治疗的药理学原则及其临床实践意义:眼科医生入门》的评论:aflibercept 8 mg“眼内清除更慢”说法存疑
Comment on: ‘Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist’
针对 Ezzine 等关于玻璃体腔抗 VEGF 治疗药理学原则的综述,del Amo 等人在 Eye 发表的通讯指出,其中 aflibercept 8 mg 相较 2 mg“眼内清除更慢”的概念尚未获验证。作者提到,被引用的群体药代动力学(popPK)模型模拟称 aflibercept 8 mg 因清除更慢可将 VEGF 抑制延长 6 至 8.9 周,但该解读需谨慎对待。
- Correspondence
- Published: 03 October 2026
Eye (2026) Cite this article
To the Editor:
We read with great interest the review by Ezzine et al. discussing the pharmacological principles of intravitreal anti-VEGF therapies [1]. While providing a useful overview, the pharmacokinetic interpretation warrants caution. In particular, the unverified concept of “slower ocular clearance” for aflibercept 8 mg versus 2 mg needs consideration. The authors highlight a population pharmacokinetic (popPK) model simulation claiming that aflibercept 8 mg prolongs VEGF suppression by 6 to 8.9 weeks due to a “slower ocular clearance” [2].
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Subscribe to this journal
Receive 18 print issues and online access
251,40 € per year
only 13,97 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
Additional access options:

Data availability
The simulation model, equations, and parameter datasets generated during the current study are available from the corresponding author upon reasonable request.
References
Ezzine S, Gale R, Bailey C, Patel PJ, Sivaprasad S, Keshk Z, et al. Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist. Eye. 2026. https://doi.org/10.1038/s41433-026-04540-y.
Kaiser PK, Turner KC, Bihorel S, Chiu J, Harnisch L, Chittenden J, et al. Population pharmacokinetic modeling and simulation of ocular clearance for aflibercept 8 mg and 2 mg and association with durability of effect [abstract]. Investig Ophthalmol Vis Sci. 2024;65:3154 https://doi.org/10.1167/iovs.65.7.3154.
Birkett DJ. Pharmacokinetics made easy. 2nd ed. Sydney: McGraw-Hill Australia; 2010.
Garcia-Quintanilla L, Luaces-Rodríguez A, Gil-Martínez M, Mondelo-García C, Maroñas O, Mangas-Sanjuán V, et al. Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration. Pharmaceutics. 2019;11:365.
Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507–32.
Funding
The authors received no specific financial support or external funding for the research, authorship, and/or publication of this article.
Author information
Authors and Affiliations
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland
Eva M. del Amo
Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Valencia, Spain
Víctor Mangas-Sanjuán
FarmaCHUSLab Group & Pharmacy Department, Hospital Clínico Universitario de Santiago de Compostela (SERGAS), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain
Anxo Fernández-Ferreiro
Authors
- Eva M. del Amo
- Víctor Mangas-Sanjuán
- Anxo Fernández-Ferreiro
Contributions
A.F.F., V.M.S. and E.M.dA. conceptualised the correspondence letter, wrote, reviewed, and approved the final manuscript.
Corresponding author
Correspondence to Anxo Fernández-Ferreiro.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
del Amo, E.M., Mangas-Sanjuán, V. & Fernández-Ferreiro, A. Comment on: ‘Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist’. Eye (2026). https://doi.org/10.1038/s41433-026-04922-2
Received: 23 June 2026
Revised: 02 September 2026
Accepted: 15 September 2026
Published: 03 October 2026
Version of record: 03 October 2026
DOI: https://doi.org/10.1038/s41433-026-04922-2
来源:Nature 健康护理主题 · nature.com